ArticleEClinicalMedicine2026
Weight loss and blood pressure lowering with GLP-1 receptor agonists and multi-hormone receptor modulators in overweight and obesity: a systematic review and meta-regression of phase 3 clinical trials.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity and hypertension frequently coexist, and weight-reduction is recommended as a core strategy for blood pressure (BP) management in adults with overweight or obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and emerging multi-hormone receptor modulators (MHRMs) induce substantial weight loss alongside modest BP reductions. However, the extent to which weight-loss is associated with BP lowering across these therapies remains unclear. Methods: We conducted a systematic review and meta-analysis of phase 3 randomized controlled trials evaluating GLP-1RAs and MHRMs in adults with overweight or obesity (PROSPERO: CRD420251146441). We searched Ovid MEDLINE, Ovid Embase, the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials from 1946 to December 2025. Risk of bias was assessed using the revised Cochrane Risk of Bias tool. Placebo-adjusted changes in body weight and BP at each trial's primary endpoint were pooled using random-effects meta-analysis with inverse-variance weighting. Meta-regression assessed the association between weight loss and BP reduction. Findings: Thirty-seven trials including 50,171 participants were analysed. Thirty-six trials had low risk of bias across all domains. Across all trials, 50% of participants were females, 16% had type 2 diabetes and 57% had hypertension. Median treatment duration was 68 weeks. Mean placebo-adjusted weight loss was -10.1% (95% CI -11.3 to -9.0) accompanied by a -4.9 mmHg (95% CI -5.5 to -4.3) reduction in systolic BP. Between-trial meta-regression showed that 76% of the variance in systolic BP reduction was explained by differences in weight loss (R Interpretation: Across phase 3 trials of GLP-1RAs and MHRMs, greater weight loss was strongly associated with larger reductions in BP, supporting pharmacological weight-loss therapies as an adjunct strategy for BP management in obesity. Funding: None.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.